BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 506 filers reported holding BIO-TECHNE CORP in Q2 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,037,410 | -10.7% | 15,192 | +8.3% | 0.01% | -12.5% |
| Q4 2022 | $1,162,089 | -2.6% | 14,022 | +233.8% | 0.01% | 0.0% |
| Q3 2022 | $1,193,000 | +89.4% | 4,201 | +131.1% | 0.01% | +60.0% |
| Q2 2022 | $630,000 | -92.1% | 1,818 | -89.6% | 0.01% | -90.7% |
| Q1 2022 | $7,993,000 | -77.4% | 17,436 | -74.5% | 0.05% | -76.1% |
| Q4 2021 | $35,418,000 | +34.4% | 68,461 | +25.9% | 0.23% | +26.3% |
| Q3 2021 | $26,343,000 | -4.6% | 54,366 | -11.3% | 0.18% | -5.3% |
| Q2 2021 | $27,607,000 | -16.4% | 61,313 | -43.4% | 0.19% | -31.3% |
| Q1 2021 | $33,030,000 | -3.9% | 108,283 | -0.0% | 0.28% | +1.1% |
| Q4 2020 | $34,388,000 | +26.1% | 108,287 | -1.7% | 0.27% | +6.2% |
| Q3 2020 | $27,276,000 | -7.2% | 110,110 | -1.1% | 0.26% | -17.4% |
| Q2 2020 | $29,391,000 | -19.6% | 111,295 | -34.7% | 0.31% | -23.5% |
| Q1 2020 | $36,548,000 | -2.2% | 170,321 | +0.0% | 0.40% | +1.0% |
| Q4 2019 | $37,384,000 | +47.1% | 170,307 | +31.1% | 0.40% | +19.0% |
| Q3 2019 | $25,409,000 | +13.3% | 129,857 | +20.2% | 0.34% | +20.4% |
| Q2 2019 | $22,422,000 | +4.2% | 108,017 | -0.4% | 0.28% | +1.8% |
| Q1 2019 | $21,527,000 | +76.1% | 108,417 | +28.3% | 0.28% | +46.3% |
| Q4 2018 | $12,227,000 | -25.8% | 84,489 | +4.7% | 0.19% | -14.2% |
| Q3 2018 | $16,472,000 | +120.0% | 80,700 | +59.5% | 0.22% | +85.6% |
| Q2 2018 | $7,487,000 | +12.7% | 50,600 | +15.0% | 0.12% | +4.4% |
| Q1 2018 | $6,646,000 | +16.6% | 44,000 | 0.0% | 0.11% | +14.1% |
| Q4 2017 | $5,700,000 | -33.1% | 44,000 | -37.6% | 0.10% | -33.6% |
| Q3 2017 | $8,523,000 | +5.9% | 70,500 | +2.9% | 0.15% | -1.3% |
| Q2 2017 | $8,049,000 | +10.7% | 68,500 | -4.2% | 0.15% | +7.1% |
| Q1 2017 | $7,268,000 | +2.4% | 71,500 | +3.6% | 0.14% | -13.5% |
| Q4 2016 | $7,095,000 | +194.5% | 69,000 | +213.6% | 0.16% | +181.0% |
| Q3 2016 | $2,409,000 | -11.0% | 22,000 | -8.3% | 0.06% | -17.1% |
| Q2 2016 | $2,707,000 | +20.0% | 24,000 | 0.0% | 0.07% | +25.0% |
| Q1 2016 | $2,256,000 | -28.6% | 24,000 | -31.6% | 0.06% | -34.1% |
| Q4 2015 | $3,160,000 | +6.4% | 35,110 | +9.3% | 0.08% | +16.4% |
| Q3 2015 | $2,969,000 | -31.5% | 32,110 | -27.0% | 0.07% | -18.9% |
| Q2 2015 | $4,333,000 | -39.2% | 44,000 | -38.0% | 0.09% | -37.1% |
| Q1 2015 | $7,122,000 | +22.4% | 71,000 | +12.7% | 0.14% | +17.2% |
| Q4 2014 | $5,821,000 | – | 63,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |